肺动脉高压中血管平滑肌细胞的表型多样性:治疗启示
本文综述肺动脉高压(PAH)中肺动脉平滑肌细胞的表型多样性,描述血管壁收缩性细胞的来源及其在PAH发病和进展中的作用,并讨论潜在靶点分子与未来治疗方向。
要点
- 肺动脉平滑肌细胞可动态调节表型,在生理和病理血管重塑中起核心作用
- PAH中收缩性细胞起源于血管中膜和非中膜,参与多种肺血管病变
- 综述提出特定潜在靶点分子,有望拓宽PAH治疗选择
核心结论
- 肺动脉平滑肌细胞表型多样性参与PAH发病和进展,靶向其表型调控可能拓宽治疗选择。
研究设计与样本
- 综述,描述肺动脉血管壁收缩性细胞的中膜和非中膜起源,汇总其参与PAH起始和进展的证据。
主要发现
- 肺动脉平滑肌细胞具有动态调节表型的能力,以维持收缩和合成功能,在生理和病理血管重塑中起核心作用。
- 收缩性细胞的中膜和非中膜起源参与PAH相关多种肺血管病变的发生和进展。
临床怎么用
- 关注肺动脉平滑肌细胞表型调控作为PAH潜在治疗方向,并探索综述提及的靶点分子。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary arterial hypertension (PAH) is a progressive incurable condition that is characterized by extensive remodeling of the pulmonary circulation, leading to severe right-sided heart failure and death. Similar to other vascular contractile cells, pulmonary arterial smooth muscle cells play central roles in physiological and pathologic vascular remodeling because of their remarkable ability to dynamically modulate their phenotype to ensure contractile and synthetic functions. The dysfunction and molecular mechanisms underlying their contribution to the various pulmonary vascular lesions associated with PAH have been a major focus of research. The aim of this review is to describe the medial and nonmedial origins of contractile cells in the pulmonary vascular wall and present evidence of how they contribute to the onset and progression of PAH. We also highlight specific potential target molecules and discuss future directions that are being explored to widen the therapeutic options for the treatment of PAH.
引用
- Lechartier B, Berrebeh N, Huertas A, et al. Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension: Implications for Therapy. Chest. 2021. PMID: 34391758. doi:10.1016/j.chest.2021.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。